Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results -- New long-term survival data disclosed from ELPIS I trial of Lomecel-B TM for Hypoplastic Left Heart Syndrome; Data reinforce p

Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results

New long-term survival data disclosed from ELPIS I trial of Lomecel-BTM for Hypoplastic Left Heart Syndrome; Data reinforce

potential mortality benefit --

First patient dosed in Phase 2 clinical trial of Lomecel-BTM for Aging-Related Frailty in Japan --

Conference call scheduled for 8:30 a.m. ET today --

Florida - May 12, 2023- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or the "Company"), a clinical

stage biotechnology company developing regenerative medicines for unmet medical needs, today provided a business update and reported

its financial results for the first quarter ended March 31, 2023.

2023, we have continued to make steady progress advancing Lomecel-BTM, our lead investigational product, across three clinical

programs," said Wa'el Hashad, Chief Executive Officer. "Since joining the Company in March, I am very excited about

the progress of Lomecel-BTM in HLHS, a rare and life-threatening congenital heart disease. Earlier this week, we provided

long-term follow-up data from our ELPIS I trial of Lomecel-BTM for infants with HLHS, which showed a 100% survival rate up

to 5 years. Also notably, the first patient was treated with Lomecel-BTM in our Phase 2 clinical trial in patients with Aging-Related

Frailty in Japan. We plan to continue to execute on key milestones across our three clinical programs, and from our Phase 2a CLEAR MIND

trial for Alzheimer's Disease, we expect to announce topline results by the end of this year."

Quarter Business Updates:

for Hypoplastic Left Heart Syndrome (HLHS):

for Aging-Related Frailty:

for Alzheimer's Disease:

Results for First Quarter Ended March 31, 2023

Revenue for the first quarters of 2023 and 2022 was $0.3 million and $0.4 million, respectively. Revenue consisted of:

Expenses: Research and development expenses in the first quarter 2023 were $2.8 million compared to $1.4 million for the same period

in 2022. The increase of $1.4 million, or 94%, was primarily due to an increase of $1.1 million in research and development expenses

that were not reimbursable by grants. Equity-based compensation allocated to research and development expenses increased to $0.3 million

for the three months ended March 31, 2023, from $0.1 million for the same period in 2022.

Expenses: General and administrative expenses in the first quarter 2023 were $1.9 million compared to $2.0 million for the same period

in 2022. The decrease of approximately $0.1 million, or 5%, was primarily related to a decrease in equity-based compensation expenses

allocated to general and administrative expenses.

Loss: Net loss was $4.6 million in the first quarter 2023 compared to $3.5 million for the same period in 2022.

Share: Net loss per share was $0.22 in the first quarter 2023 compared to $0.17 for the same period in 2022.

Cash and marketable securities:

Cash and marketable securities was $13.7 million and $19.6 million as of March 31, 2023, and December 31, 2022, respectively.

reclassifications have been made to prior year financial statements to conform to classifications used in the current year. These reclassifications

had no impact on net loss, shareholders' equity or cash flows as previously reported.

on the Company's current operating plan and financial resources, we believe that our existing cash and marketable securities will

be sufficient to cover expenses and capital requirements into the second quarter of 2024.

will host a conference call today at 8:30 a.m. ET to discuss the Company's first quarter 2023 financial results and provide a business

Dial-in Number: 833-470-1428

Dial-in Number: 833-950-0062

Other Locations Dial-in Number: 929-526-1599

Replay Dial-in Number: 866-813-9403

Other Locations Dial-in Number: 44-204-525-0658

audio webcast of the call may also be accessed from the Investors' page of the Longeveron website at www.longeveron.com.

A replay of the call will be available on the Longeveron website shortly after completion of the call.

is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead

investigational product is Lomecel-B , an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow

of young, healthy adult donors. Lomecel-B has multiple mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory,

and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Longeveron is currently advancing

Lomecel-B through clinical trials in three indications: hypoplastic left heart syndrome (HLHS), Alzheimer's Disease, and

Aging-Related Frailty. Additional information about the Company is available at www.longeveron.com.

statements in this press release that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions

of the Private Securities Litigation Reform Act of 1995, which reflect management's current expectations, assumptions, and estimates

of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ

materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of

forward-looking terminology such as "believe," "expects," "may," "looks to," "will,"

"should," "plan," "intend," "on condition," "target," "see," "potential,"

"estimates," "preliminary," or "anticipates" or the negative thereof or comparable terminology, or by discussion

of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially

from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements about the

ability of Longeveron's clinical trials to demonstrate safety and efficacy of the Company's product candidates, and other

positive results; the timing and focus of the Company's ongoing and future preclinical studies and clinical trials and the reporting

of data from those studies and trials; the size of the market opportunity for the Company's product candidates, including its estimates

of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available;

the beneficial characteristics, safety, efficacy and therapeutic effects of the Company's product candidates; the Company's

ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company's

plans relating to the further development of its product candidates, including additional disease states or indications it may pursue;

the Company's plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms

where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel

and the Company's ability to attract and retain such personnel; the Company's estimates regarding expenses, future revenue,

capital requirements and needs for additional financing; the Company's need to raise additional capital, and the difficulties it

may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company's financial performance,

and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses

and capital expenditure requirements. Further information relating to factors that may impact the Company's results and forward-looking

statements are disclosed in the Company's filings with the Securities and Exchange Commission, including Longeveron's Annual Report

on Form 10-K for the year ended December 31, 2022, filed with the SEC on March 14, 2023. The forward-looking statements contained in

this press release are made as of the date of this press release, and the Company disclaims any intention or obligation, other than imposed

by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Statements of Operations

(In thousands, except per share data)

accompanying notes to unaudited condensed financial statements.